Intravesical chemotherapy for maximum prophylaxis of new early phase superficial bladder carcinoma treated by transurethral resection

A combined analysis of trials by the Japanese Urological Cancer Research Group using smoothed hazard function

Shiro Hinotsu, Hideyuki Akaza, Yasuo Ohashi, Toshihiko Kotake

Research output: Contribution to journalArticle

76 Citations (Scopus)

Abstract

BACKGROUND. The effect of intravesical instillation of doxorubicin or epirubicin after transurethral resection (TUR) was estimated from the data of five randomized clinical trials in Japan. The authors provided the estimated hazard function plots with a smoothing technique, to evaluate the prophylactic effect of an intravesical therapy over time and to estimate the natural history of superficial bladder carcinoma. METHODS. Data on a total of 1732 patients from 5 studies of the Japanese Urological Cancer Research Group who were eligible to receive doxorubicin and epirubicin were analyzed. The patients were divided into four subgroups based on their background characteristics. Their tumors were categorized as 'primary and solitary,' 'primary and multiple,' 'recurrent and solitary,' or 'recurrent and multiple.' RESULTS. Multivariate analysis revealed that intravesical instillation reduced the risk of recurrence to about one-half to two-thirds compared with the controls. The shapes of the graphs that estimated the hazard function for patients with no prophylaxis indicated that multiple tumors showed an earlier peak of recurrence than solitary tumors and recurrent tumors had a higher hazard of recurrence than primary tumors. Graphic presentation of the hazard function in each subgroup suggested that the effect of prophylaxis continued for 500 days after TUR but not for longer. CONCLUSIONS. This analysis indicated that there are two patterns of tumor recurrence of superficial bladder carcinoma after TUR, namely, early phase and late phase. Intravesical chemotherapy may be effective mainly in reducing the hazard for recurrence in the early phase.

Original languageEnglish
Pages (from-to)1818-1826
Number of pages9
JournalCancer
Volume86
Issue number9
DOIs
Publication statusPublished - Nov 1 1999
Externally publishedYes

Fingerprint

Urologic Neoplasms
Urinary Bladder
Carcinoma
Drug Therapy
Recurrence
Research
Intravesical Administration
Neoplasms
Epirubicin
Doxorubicin
Natural History
Japan
Multivariate Analysis
Randomized Controlled Trials

Keywords

  • Combined analysis
  • Intravesical chemotherapy
  • Smoothed hazard
  • Superficial bladder carcinoma

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Intravesical chemotherapy for maximum prophylaxis of new early phase superficial bladder carcinoma treated by transurethral resection : A combined analysis of trials by the Japanese Urological Cancer Research Group using smoothed hazard function. / Hinotsu, Shiro; Akaza, Hideyuki; Ohashi, Yasuo; Kotake, Toshihiko.

In: Cancer, Vol. 86, No. 9, 01.11.1999, p. 1818-1826.

Research output: Contribution to journalArticle

@article{acf7437ff7074ac59536077cfef1f750,
title = "Intravesical chemotherapy for maximum prophylaxis of new early phase superficial bladder carcinoma treated by transurethral resection: A combined analysis of trials by the Japanese Urological Cancer Research Group using smoothed hazard function",
abstract = "BACKGROUND. The effect of intravesical instillation of doxorubicin or epirubicin after transurethral resection (TUR) was estimated from the data of five randomized clinical trials in Japan. The authors provided the estimated hazard function plots with a smoothing technique, to evaluate the prophylactic effect of an intravesical therapy over time and to estimate the natural history of superficial bladder carcinoma. METHODS. Data on a total of 1732 patients from 5 studies of the Japanese Urological Cancer Research Group who were eligible to receive doxorubicin and epirubicin were analyzed. The patients were divided into four subgroups based on their background characteristics. Their tumors were categorized as 'primary and solitary,' 'primary and multiple,' 'recurrent and solitary,' or 'recurrent and multiple.' RESULTS. Multivariate analysis revealed that intravesical instillation reduced the risk of recurrence to about one-half to two-thirds compared with the controls. The shapes of the graphs that estimated the hazard function for patients with no prophylaxis indicated that multiple tumors showed an earlier peak of recurrence than solitary tumors and recurrent tumors had a higher hazard of recurrence than primary tumors. Graphic presentation of the hazard function in each subgroup suggested that the effect of prophylaxis continued for 500 days after TUR but not for longer. CONCLUSIONS. This analysis indicated that there are two patterns of tumor recurrence of superficial bladder carcinoma after TUR, namely, early phase and late phase. Intravesical chemotherapy may be effective mainly in reducing the hazard for recurrence in the early phase.",
keywords = "Combined analysis, Intravesical chemotherapy, Smoothed hazard, Superficial bladder carcinoma",
author = "Shiro Hinotsu and Hideyuki Akaza and Yasuo Ohashi and Toshihiko Kotake",
year = "1999",
month = "11",
day = "1",
doi = "10.1002/(SICI)1097-0142(19991101)86:9<1818::AID-CNCR25>3.0.CO;2-0",
language = "English",
volume = "86",
pages = "1818--1826",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "9",

}

TY - JOUR

T1 - Intravesical chemotherapy for maximum prophylaxis of new early phase superficial bladder carcinoma treated by transurethral resection

T2 - A combined analysis of trials by the Japanese Urological Cancer Research Group using smoothed hazard function

AU - Hinotsu, Shiro

AU - Akaza, Hideyuki

AU - Ohashi, Yasuo

AU - Kotake, Toshihiko

PY - 1999/11/1

Y1 - 1999/11/1

N2 - BACKGROUND. The effect of intravesical instillation of doxorubicin or epirubicin after transurethral resection (TUR) was estimated from the data of five randomized clinical trials in Japan. The authors provided the estimated hazard function plots with a smoothing technique, to evaluate the prophylactic effect of an intravesical therapy over time and to estimate the natural history of superficial bladder carcinoma. METHODS. Data on a total of 1732 patients from 5 studies of the Japanese Urological Cancer Research Group who were eligible to receive doxorubicin and epirubicin were analyzed. The patients were divided into four subgroups based on their background characteristics. Their tumors were categorized as 'primary and solitary,' 'primary and multiple,' 'recurrent and solitary,' or 'recurrent and multiple.' RESULTS. Multivariate analysis revealed that intravesical instillation reduced the risk of recurrence to about one-half to two-thirds compared with the controls. The shapes of the graphs that estimated the hazard function for patients with no prophylaxis indicated that multiple tumors showed an earlier peak of recurrence than solitary tumors and recurrent tumors had a higher hazard of recurrence than primary tumors. Graphic presentation of the hazard function in each subgroup suggested that the effect of prophylaxis continued for 500 days after TUR but not for longer. CONCLUSIONS. This analysis indicated that there are two patterns of tumor recurrence of superficial bladder carcinoma after TUR, namely, early phase and late phase. Intravesical chemotherapy may be effective mainly in reducing the hazard for recurrence in the early phase.

AB - BACKGROUND. The effect of intravesical instillation of doxorubicin or epirubicin after transurethral resection (TUR) was estimated from the data of five randomized clinical trials in Japan. The authors provided the estimated hazard function plots with a smoothing technique, to evaluate the prophylactic effect of an intravesical therapy over time and to estimate the natural history of superficial bladder carcinoma. METHODS. Data on a total of 1732 patients from 5 studies of the Japanese Urological Cancer Research Group who were eligible to receive doxorubicin and epirubicin were analyzed. The patients were divided into four subgroups based on their background characteristics. Their tumors were categorized as 'primary and solitary,' 'primary and multiple,' 'recurrent and solitary,' or 'recurrent and multiple.' RESULTS. Multivariate analysis revealed that intravesical instillation reduced the risk of recurrence to about one-half to two-thirds compared with the controls. The shapes of the graphs that estimated the hazard function for patients with no prophylaxis indicated that multiple tumors showed an earlier peak of recurrence than solitary tumors and recurrent tumors had a higher hazard of recurrence than primary tumors. Graphic presentation of the hazard function in each subgroup suggested that the effect of prophylaxis continued for 500 days after TUR but not for longer. CONCLUSIONS. This analysis indicated that there are two patterns of tumor recurrence of superficial bladder carcinoma after TUR, namely, early phase and late phase. Intravesical chemotherapy may be effective mainly in reducing the hazard for recurrence in the early phase.

KW - Combined analysis

KW - Intravesical chemotherapy

KW - Smoothed hazard

KW - Superficial bladder carcinoma

UR - http://www.scopus.com/inward/record.url?scp=0033229743&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033229743&partnerID=8YFLogxK

U2 - 10.1002/(SICI)1097-0142(19991101)86:9<1818::AID-CNCR25>3.0.CO;2-0

DO - 10.1002/(SICI)1097-0142(19991101)86:9<1818::AID-CNCR25>3.0.CO;2-0

M3 - Article

VL - 86

SP - 1818

EP - 1826

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 9

ER -